Thyroid hormone receptor mutants implicated in human hepatocellular carcinoma display an altered target gene repertoire

Oncogene

Volumn 28, Issue 47, 2009, Pages 4162-4174

  Chan, I H ^a   Privalsky, M L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dominant negative; Gene expression; Hepatocellular carcinoma; Mutant; Thyroid hormone receptors

Indexed keywords

DNA; ONCOPROTEIN; THYROID HORMONE RECEPTOR;

ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; GENE ACTIVATION; GENE CONTROL; GENE MUTATION; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN MICROARRAY; STEM CELL; WILD TYPE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MUTATION; NEOPLASM PROTEINS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, THYROID HORMONE;

EID: 70949101412     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.265     Document Type: Article

References (69)

1. Barlow C, Meister B, Lardelli M, Lendahl U, Vennstrom B. (1994). Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v-erbA. EMBO J 13: 4241-4250.
2. Berghagen H, Ragnhildstveit E, Krogsrud K, Thuestad G, Apriletti J, Saatcioglu F. (2002). Corepressor SMRT functions as a coactivator for thyroid hormone receptor T3Ralpha from a negative hormone response element. J Biol Chem 277: 49517-49522.
3. Bonde BG, Privalsky ML. (1990). Sequence-specific DNA binding by the v-erbA oncogene protein of avian erythroblastosis virus. J Virol 64: 1314-1320.
4. Brent GA. (2000). Tissue-specific actions of thyroid hormone: insights from animal models. Rev Endocr Metab Disord 1: 27-33.
5. Buchholz DR, Paul BD, Fu L, Shi YB. (2006). Molecular and developmental analyses of thyroid hormone receptor function in Xenopus laevis, the African clawed frog. Gen Comp Endocrinol 145: 1-19.
6. Chamba A, Neuberger J, Strain A, Hopkins J, Sheppard MC, Franklyn JA. (1996). Expression and function of thyroid hormone receptor variants in normal and chronically diseased human liver. J Clin Endocrinol Metab 81: 360-367.
7. Chan IH, Privalsky ML. (2006). Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs. Oncogene 25: 3576-3588.
8. Chen H, Smit-McBride Z, Lewis S, Sharif M, Privalsky ML. (1993). Nuclear hormone receptors involved in neoplasia: erb A exhibits a novel DNA sequence specificity determined by amino acids outside of the zinc-finger domain. Mol Cell Biol 13: 2366-2376.
9. Cheng SY. (2000). Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Rev Endocr Metab Disord 1: 9-18.
10. Cheng SY. (2003). Thyroid hormone receptor mutations in cancer. Mol Cell Endocrinol 213: 23-30.
11. Cheng SY. (2005). Thyroid hormone receptor mutations and disease: beyond thyroid hormone resistance. Trends Endocrinol Metab 16: 176-182.
12. Damm K, Thompson CC, Evans RM. (1989). Protein encoded by v-erbA functions as a thyroid-hormone receptor antagonist. Nature 339: 593-597.
13. Darby IA, Bouhnik J, Coezy ED, Corvol P. (1991). Thyroid hormone receptors and stimulation of angiotensinogen production in HepG2 cells. in vitro Cell Dev Biol 27: 21-24.
14. DeGroot LJ. (1996). Resistance to thyroid hormone. Ann Intern Med 125: 623.
15. Desbois C, Aubert D, Legrand C, Pain B, Samarut J. (1991). A novel mechanism of action for v-ErbA: abrogation of the inactivation of transcription factor AP-1 by retinoic acid and thyroid hormone receptors. Cell 67: 731-740.
16. Flamant F, Baxter JD, Forrest D, Refetoff S, Samuels H, Scanlan TS et al. (2006). International Union of Pharmacology. LIX. The pharmacology and classification of the nuclear receptor superfamily: thyroid hormone receptors. Pharmacol Rev 58: 705-711.
17. Furumoto H, Ying H, Chandramouli GV, Zhao L, Walker RL, Meltzer PS et al. (2005). An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblas-toma/E2F pathway and induces pituitary tumorigenesis. Mol Cell Biol 25: 124-135.
18. Furuya F, Hanover JA, Cheng SY. (2006). Activation of phosphati-dylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proc Natl Acad Sci USA 103: 1780-1785.
19. Garcia-Silva S, Aranda A. (2004). The thyroid hormone receptor is a suppressor of ras-mediated transcription, proliferation, and transformation. Mol Cell Biol 24: 7514-7523.
20. Gonzalez-Sancho JM, Garcia V, Bonilla F, Munoz A. (2003). Thyroid hormone receptors/THR genes in human cancer. Cancer Lett 192: 121-132.
21. Graf T, Beug H. (1983). Role of the v-erbA and v-erbB oncogenes of avian erythroblastosis virus in erythroid cell transformation. Cell 34: 7-9.
22. Harvey CB, Williams GR. (2002). Mechanism of thyroid hormone action. Thyroid 12: 441-446.
23. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U et al. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
24. Kamiya Y, Puzianowska-Kuznicka M, McPhie P, Nauman J, Cheng SY, Nauman A. (2002). Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma. Carcinogenesis 23: 25-33.
25. Katz RW, Koenig RJ. (1993). Nonbiased identification of DNA sequences that bind thyroid hormone receptor alpha 1 with high affinity. J Biol Chem 268: 19392-19397.
26. Kopp P, Kitajima K, Jameson JL. (1996). Syndrome of resistance to thyroid hormone: insights into thyroid hormone action. Proc Soc Exp Biol Med 211: 49-61.
27. Lazar MA. (1993). Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev 14: 184-193.
28. Lazar MA. (2003). Thyroid hormone action: a binding contract. J Clin Invest 112: 497-499.
29. Lee AY, He B, You L, Xu Z, Mazieres J, Reguart N et al. (2004). Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma. Biochem Biophys Res Commun 323: 1246-1250.
30. Lin KH, Shieh HY, Chen SL, Hsu HC. (1999). Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog 26: 53-61.
31. Lin KH, Zhu XG, Hsu HC, Chen SL, Shieh HY, Chen ST et al. (1997). Dominant negative activity of mutant thyroid hormone alpha1 receptors from patients with hepatocellular carcinoma. Endocrinology 138: 5308-5315.
32. Lin KH, Zhu XG, Shieh HY, Hsu HC, Chen ST, McPhie P et al. (1996). Identification of naturally occurring dominant negative mutants of thyroid hormone alpha 1 and beta 1 receptors in a human hepatocellular carcinoma cell line. Endocrinology 137: 4073-4081.
33. Martinez-Iglesias O, Garcia-Silva S, Tenbaum SP, Regadera J, Larcher F, Paramio JM et al. (2009). Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Res 69: 501-509.
34. Matsushita A, Sasaki S, Kashiwabara Y, Nagayama K, Ohba K, Iwaki H et al. (2007). Essential role of GATA2 in the negative regulation of thyrotropin beta gene by thyroid hormone and its receptors. Mol Endocrinol 21: 865-884.
35. Meyer T, Starr DB, Carlstedt-Duke J. (1997). The rat glucocorticoid receptor mutant K461A differentiates between two different mechanisms of transrepression. J Biol Chem 272: 21090-21095.
36. Mikheev AM, Mikheeva SA, Maxwell JP, Rivo JV, Rostomily R, Swisshelm K et al. (2008). Dickkopf-1 mediated tumor suppression in human breast carcinoma cells. Breast Cancer Res Treat 112: 263-273.
37. Miller LD, Park KS, Guo QM, Alkharouf NW, Malek RL, Lee NH et al. (2001). Silencing of Wnt signaling and activation of multiple metabolic pathways in response to thyroid hormone-stimulated cell proliferation. Mol Cell Biol 21: 6626-6639.
38. Murata Y. (1998). Multiple isoforms of thyroid hormone receptor: an analysis of their relative contribution in mediating thyroid hormone action. Nagoya J Med Sci 61: 103-115.
39. Nygard M, Wahlstrom GM, Gustafsson MV, Tokumoto YM, Bondesson M. (2003). Hormone-dependent repression of the E2F-1 gene by thyroid hormone receptors. Mol Endocrinol 17: 79-92.
40. Privalsky ML. (1992). v-erb A, nuclear hormone receptors, and oncogenesis. Biochim Biophys Acta 1114: 51-62.
41. Privalsky ML. (2008). Thryoid Hormone Receptors, Coregulators, and Disease. World Scientific Publishing, Ltd.: London.
42. Puzianowska-Kuznicka M, Krystyniak A, Madej A, Cheng SY, Nauman J. (2002). Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab 87: 1120-1128.
43. Ramachandran V, Arumugam T, Wang H, Logsdon CD. (2008). Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res 68: 7811-7818.
44. Rastinejad F, Perlmann T, Evans RM, Sigler PB. (1995). Structural determinants of nuclear receptor assembly on DNA direct repeats. Nature 375: 203-211.
45. Refetoff S. (1993). Resistance to thyroid hormone. Clin Lab Med 13: 563-581.
46. Refetoff S, Weiss RE, Usala SJ. (1993). The syndromes of resistance to thyroid hormone. Endocr Rev 14: 348-399.
47. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. (2006). GenePattern 2.0. Nat Genet 38: 500-501.
48. Ricciardelli C, Sakko AJ, Ween MP, Russell DL, Horsfall DJ. (2009). The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev 28: 233-245.
49. Rietveld LE, Caldenhoven E, Stunnenberg HG. (2001). Avian erythroleukemia: a model for corepressor function in cancer. Oncogene 20: 3100-3109.
50. Rosen MD, Privalsky ML. (2009). Thyroid hormone receptors involved in renal clear cell carcinoma alter corepressor release and reveal helix 12 as a key determinant of corepressor specificity. Mol Endocrinol 23: 1183-1192.
51. Sap J, Munoz A, Damm K, Goldberg Y, Ghysdael J, Leutz A et al. (1986). The c-erb-A protein is a high-affinity receptor for thyroid hormone. Nature 324: 635-640.
52. Sharif M, Privalsky ML. (1991). v-erbA oncogene function in neoplasia correlates with its ability to repress retinoic acid receptor action. Cell 66: 885-893.
53. Sharif M, Privalsky ML. (1992). V-erbA and c-erbA proteins enhance transcriptional activation by c-jun. Oncogene 7: 953-960.
54. Smyth GK. (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
55. Starr DB, Matsui W, Thomas JR, Yamamoto KR. (1996). Intracel-lular receptors use a common mechanism to interpret signaling information at response elements. Genes Dev 10: 1271-1283.
56. Tagami T, Madison LD, Nagaya T, Jameson JL. (1997). Nuclear receptor corepressors activate rather than suppress basal transcription of genes that are negatively regulated by thyroid hormone. Mol Cell Biol 17: 2642-2648.
57. Theriault A, Ogbonna G, Adeli K. (1992). Thyroid hormone modulates apolipoprotein B gene expression in HepG2 cells. Biochem Biophys Res Commun 186: 617-623.
58. Tsai CC, Fondell JD. (2004). Nuclear receptor recruitment of histone-modifying enzymes to target gene promoters. Vitam Horm 68: 93-122.
59. Uht RM, Webb P, Nguyen P, Price Jr RH, Valentine C, Favre H et al. (2004). A conserved lysine in the estrogen receptor DNA binding domain regulates ligand activation profiles at AP-1 sites, possibly by controlling interactions with a modulating repressor. Nucl Recept 2: 2.
60. Vadlamudi RK, Kumar R. (2003). P21-activated kinases in human cancer. Cancer Metastasis Rev 22: 385-393.
61. Ventura-Holman T, Mamoon A, Subauste JS. (2008). Modulation of expression of RA-regulated genes by the oncoprotein v-erbA. Gene 425: 23-27.
62. Vogelstein B, Kinzler KW. (2004). Cancer genes and the pathways they control. Nat Med 10: 789-799.
63. Weinberger C, Thompson CC, Ong ES, Lebo R, Gruol DJ, Evans RM. (1986). The c-erb-A gene encodes a thyroid hormone receptor. Nature 324: 641-646.
64. Yen PM. (2001). Physiological and molecular basis of thyroid hormone action. Physiol Rev 81: 1097-1142.
65. Yen PM. (2003). Molecular basis of resistance to thyroid hormone. Trends Endocrinol Metab 14: 327-333.
66. Yen PM, Cheng SY. (2003). Germline and somatic thyroid hormone receptor mutations in man. J Endocrinol Invest 26: 780-787.
67. Zenke M, Munoz A, Sap J, Vennstrom B, Beug H. (1990). v-erbA oncogene activation entails the loss of hormone-dependent regulator activity of c-erbA. Cell 61: 1035-1049.
68. Zhang J, Lazar MA. (2000). The mechanism of action of thyroid hormones. Annu Rev Physiol 62: 439-466.
69. Zhang L, Cui R, Cheng X, Du J. (2005). Antiapoptotic effect of serum and glucocorticoid inducible protein kinase is mediated by a novel mechanism activating IkappaB. Cancer Res 65: 457-464.